Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SLRX
- Price
- 0.63
- Stock movement up
- +0.03 (4.37%)
- Company name
- Salarius Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 902.45K
- Ent value
- -1.45M
- Price/Sales
- 50.44
- Price/Book
- 0.31
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -47.36%
- 1 year return
- -83.39%
- 3 year return
- -79.91%
- 5 year return
- -66.01%
- 10 year return
- -69.85%
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SLRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 50.44 |
| Price to Book | 0.31 |
| EV to Sales | -80.87 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.44M |
| EPS (TTM) | -3.90 |
| FCF per share (TTM) | -4.13 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 17.89K |
| Gross profit (TTM) | 14.57K |
| Operating income (TTM) | -5.22M |
| Net income (TTM) | -4.99M |
| EPS (TTM) | -3.90 |
| EPS (1y forward) | -187.84 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 81.46% |
| Operating margin (TTM) | -29154.42% |
| Profit margin (TTM) | -27909.90% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 3.28M |
| Net receivables | 0.00 |
| Total current assets | 3.82M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 3.86M |
| Accounts payable | 165.80K |
| Short/Current long term debt | 328.85K |
| Total current liabilities | 494.65K |
| Total liabilities | 934.58K |
| Shareholder's equity | 2.92M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -5.29M |
| Capital expenditures (TTM) | 4.00 |
| Free cash flow (TTM) | -5.29M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -170.75% |
| Return on Assets | -129.40% |
| Return on Invested Capital | -153.49% |
| Cash Return on Invested Capital | -162.72% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.59 |
| Daily high | 0.63 |
| Daily low | 0.58 |
| Daily Volume | 17K |
| All-time high | 120850.00 |
| 1y analyst estimate | 26.00 |
| Beta | 0.93 |
| EPS (TTM) | -3.90 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| SLRX | S&P500 | |
| Current price drop from All-time high | -100.00% | -12.89% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 11 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -87.18% | -11.07% |
| Avg time to new high | 285 days | 12 days |
| Max time to new high | 2511 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
902.45K
Marketcap category
Small-cap
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
Employees
2
Investor relations
-
SEC filings
CEO
David J. Arthur
Country
USA
City
Houston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page